• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    How Is The Market Feeling About Cardinal Health?

    7/16/24 10:15:13 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email

    Cardinal Health's (NYSE:CAH) short percent of float has fallen 17.69% since its last report. The company recently reported that it has 6.12 million shares sold short, which is 3.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.18 days to cover their short positions on average.

    Why Short Interest Matters

    Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

    Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

    See Also: List of the most shorted stocks

    Cardinal Health Short Interest Graph (3 Months)

    short_fig

    As you can see from the chart above the percentage of shares that are sold short for Cardinal Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.

    Comparing Cardinal Health's Short Interest Against Its Peers

    Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

    According to Benzinga Pro, Cardinal Health's peer group average for short interest as a percentage of float is 4.16%, which means the company has less short interest than most of its peers.

    Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it.

    This article was generated by Benzinga's automated content engine and was reviewed by an editor.

    Get the next $CAH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAH

    DatePrice TargetRatingAnalyst
    1/9/2026Neutral → Buy
    Citigroup
    12/9/2025$243.00Overweight
    Barclays
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $CAH
    SEC Filings

    View All

    SEC Form 10-Q filed by Cardinal Health Inc.

    10-Q - CARDINAL HEALTH INC (0000721371) (Filer)

    2/5/26 8:47:09 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    2/5/26 6:47:19 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    1/13/26 6:53:33 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on April 15, 2026 to shareholders of record at the close of business on April 1, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

    2/12/26 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 19% to $65.6 billionGAAP1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35Cardinal Health completes annual baseline share repurchase of $750 millionCardinal Health reaches targeted leverage range3DUBLIN, Ohio, Feb. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of fiscal year 2025. Second quarter GAAP operating earnings increased 29%

    2/5/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation

    Raising Fiscal 2026 Outlook: Cardinal Health is increasing expectations for fiscal year 2026 non-GAAP diluted earnings per share (EPS)1 to at least $10.00, from its prior guidance range of $9.65 to $9.85Accelerating Specialty Growth: The company expects that its Specialty revenues will surpass $50 billion in fiscal 2026, marking a 16% compounded annual growth rate (CAGR) over three years2Successfully Navigating IRA Changes: The company confirms the successful transition of its manufacturer distribution service agreements for all branded pharmaceutical products impacted by the 2026 Medicare Drug Price Negotiation ProgramIntroducing ContinuCare™ Pathway: The company's direct-to-patient at-Home

    1/13/26 6:50:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cardinal Health upgraded by Citigroup

    Citigroup upgraded Cardinal Health from Neutral to Buy

    1/9/26 8:24:26 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Barclays initiated coverage on Cardinal Health with a new price target

    Barclays initiated coverage of Cardinal Health with a rating of Overweight and set a new price target of $243.00

    12/9/25 8:43:24 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

    6/3/25 7:24:57 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hall Patricia Hemingway sold $918,880 worth of shares (4,000 units at $229.72), decreasing direct ownership by 12% to 28,264 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    2/10/26 4:13:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Chief Human Resources Officer Pitteroff Valerie Christine was granted 3,982 shares, increasing direct ownership by 99% to 8,022 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    1/20/26 7:21:53 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    New insider Pitteroff Valerie Christine claimed ownership of 4,503 shares (SEC Form 3)

    3 - CARDINAL HEALTH INC (0000721371) (Issuer)

    1/7/26 4:10:22 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/13/24 5:01:02 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    1/30/24 1:39:03 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/14/23 12:37:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Financials

    Live finance-specific insights

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on April 15, 2026 to shareholders of record at the close of business on April 1, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

    2/12/26 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 19% to $65.6 billionGAAP1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35Cardinal Health completes annual baseline share repurchase of $750 millionCardinal Health reaches targeted leverage range3DUBLIN, Ohio, Feb. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of fiscal year 2025. Second quarter GAAP operating earnings increased 29%

    2/5/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Nov. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of

    11/4/25 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Carlisle Companies Announces Leadership Appointments

    Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

    5/16/25 4:05:00 PM ET
    $CAH
    $CSL
    $SUM
    Other Pharmaceuticals
    Health Care
    Specialty Chemicals
    Industrials

    Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    3/10/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care